Clinical trials: HPV-Related Carcinoma
Head and Neck Carcinoma
Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer
This trial studies the effects of human papillomavirus diagnosis on the relationships of patients with head and neck cancer. Determining the effects of human papillomavirus diagnosis on relationships may determine whether human…
- Trial name
- NCT04666428
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Jefferson University
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Cervical Cancer, Cervical Intraepithelial Neoplasia
Dry Run of the ScreenUrSelf Trial
The proposed study is the Dry Run preceding the ScreenUrSelf trial.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia, Human Papilloma Virus, HPV-Related Cervical Carcinoma
- Trial name
- NCT05996796
- Testing
- Colli-Pee Small Volumes, Evalyn Brush
- Where
- Belgium
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
HPV Infection, HPV-Related Cervical Carcinoma
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
A total of 90 Chinese women aged 9-45 years old were divided into three age groups: 27-45 years old, 18-26 years old, and 9-17 years old. The experimental group and the placebo group were randomly assigned in a ratio of 2:1.
- Trial name
- NCT04083196
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China